pharma · No medical condition. · Generalized Myasthenia Gravis
Lacuna Pharma Pty Ltd
Lacuna Pharma Pty is a pharma organization headquartered in Colmenar Viejo, AU. Primary therapeutic focus areas include No medical condition., Generalized Myasthenia Gravis, No therapeutic indication in the current trial
Phase 1 · other · Glioblastoma
SI-053 is a temozolomide-based investigational therapy being developed by Lacuna Pharma Pty Ltd for intracranial administration in newly diagnosed glioblastoma (GBM). The program is currently in Phase 1 development, conducting an open-label dose escalation study to establish the maximum tolerated dose (MTD), identify d
Internal code DBP-053-01
SI-053 is a temozolomide-based investigational therapy being developed by Lacuna Pharma Pty Ltd for intracranial administration in newly diagnosed glioblastoma (GBM). The program is currently in Phase 1 development, conducting an open-label dose escalation study to establish the maximum tolerated dose (MTD), identify dose-limiting toxicities (DLTs), and characterize pharmacokinetics following a single intracranial dose as an add-on to standard of care. The study design reflects a precision approach to local drug delivery in a disease with limited treatment options and poor prognosis.
Glioblastoma remains one of the most aggressive primary brain tumors in adults, with median survival of approximately 15 months despite current standard-of-care treatment (Stupp protocol: external beam radiation therapy and temozolomide). The intracranial administration route for SI-053 represents a strategy to achieve high local drug concentrations while potentially reducing systemic toxicity compared to conventional intravenous temozolomide delivery.
The Phase 1 program is actively enrolling and represents an early-stage exploration of dosing and safety parameters. No regulatory approvals have been disclosed. The competitive landscape includes multiple Phase 3 programs combining temozolomide with checkpoint inhibitors, anti-angiogenic agents, and other modalities, as well as established surgical and radiation-based approaches. Key upcoming milestones will include completion of dose escalation, MTD determination, and potential advancement to Phase 2 efficacy evaluation.
Glioblastoma carries a dismal prognosis despite aggressive multimodal therapy, with median overall survival of 14–15 months in newly diagnosed patients receiving standard of care. Recurrent disease is nearly universal, and treatment options at progression remain limited. This substantial unmet medical need drives continued investigation of novel delivery approaches and drug combinations.
The intracranial delivery strategy for SI-053 addresses a key clinical challenge: achieving adequate drug concentration at the tumor site while minimizing systemic toxicity. Direct brain administration may enable higher local exposure to temozolomide or its active metabolites, potentially improving efficacy. This approach complements rather than replaces systemic therapy, positioning it as an add-on to standard care.
The competitive landscape is crowded with Phase 3 programs exploring temozolomide combinations (e.g., with Keytruda/pembrolizumab, cediranib, and other agents) and alternative chemotherapy regimens (e.g., lomustine, edotecarin). However, most competitors focus on systemic administration. SI-053's local delivery mechanism differentiates it, though clinical validation of this approach remains pending.
The patient population is substantial: approximately 10,000–12,000 new GBM diagnoses annually in the United States alone. Commercial significance depends on efficacy data, tolerability profile, and manufacturing feasibility of intracranial administration. Success could establish a new treatment paradigm for brain tumors and support expansion to other CNS malignancies.
Drug Class: Temozolomide-based investigational agent
Modality: Small molecule (implied by temozolomide backbone)
Route of Administration: Intracranial (direct brain administration)
Mechanism of Action: Not yet disclosed; presumed to involve DNA alkylation via temozolomide's active metabolite, consistent with the parent compound's mechanism
Target: Not yet disclosed
Related Therapies: Temozolomide (approved, standard of care for GBM); Stupp protocol (external beam radiation therapy + temozolomide); checkpoint inhibitor combinations (e.g., temozolomide + pembrolizumab); anti-angiogenic combinations (e.g., temozolomide + cediranib); alternative alkylating agents (e.g., lomustine)
First Approval: Not applicable; SI-053 is investigational and not approved in any jurisdiction
Patent Status: Not yet disclosed
Also known as: GBM, GBM (glioblastoma), WHO grade IV glioma, glioblastoma (disease), glioblastoma multiforme, glioblastoma multiforme (disease)
Prevalence: Point prevalence: 1-9 / 100 000 (Worldwide) — source: Orphanet, validated.
The most malignant astrocytic tumor (WHO grade IV). It is composed of poorly differentiated neoplastic astrocytes and it is characterized by the presence of cellular polymorphism, nuclear atypia, brisk mitotic activity, vascular thrombosis, microvascular proliferation and necrosis. It typically affects adults and is preferentially located in the cerebral hemispheres. It may develop from diffuse astrocytoma WHO grade II or anaplastic astrocytoma (secondary glioblastoma, IDH-mutant), but more frequently, it manifests after a short clinical history de novo, without evidence of a less malignant precursor lesion (primary glioblastoma, IDH- wildtype). (Adapted from WHO)
ClinicalTrials.gov lists 877 registered studies for Glioblastoma (AACT aggregate).
Phase breakdown: NA (252), PHASE2 (223), PHASE1 (206), PHASE1/PHASE2 (86), EARLY_PHASE1 (49), PHASE3 (45), PHASE2/PHASE3 (11), PHASE4 (5)
Common investigational therapies:
Disease data sourced from MONDO Disease Ontology (MONDO:0018177), Orphanet — glioblastoma, NCT00001148, NCT00001171, NCT00009035, NCT00028158, NCT00029783, AACT (ClinicalTrials.gov aggregate), ClinicalTrials.gov, Open Targets Platform (CC BY 4.0).
Phase 1 Dose Escalation Ongoing
Open-label dose escalation study to estimate MTD, identify DLTs, and characterize pharmacokinetics of single-dose intracranial SI-053 as add-on to standard of care in newly diagnosed GBM.
The GBM treatment landscape includes multiple competing approaches across different development stages. Established standard of care comprises surgical resection, external beam radiation therapy, and systemic temozolomide (Stupp protocol), with GammaTile radiation therapy implantation representing an approved local radiation option. Several Phase 3 programs are advancing temozolomide-based combinations: Novo Nordisk A/S is studying temozolomide + Keytruda (pembrolizumab); AstraZeneca is evaluating cediranib combined with temozolomide; and Adaptive Biotechnologies Corp is investigating temozolomide alongside ADI-PEG-20, troriluzole, and AZD1390. Lacuna Pharma Pty Ltd itself has Phase 3 programs with lomustine and Temodal (temozolomide) formulations. Alternative chemotherapy agents in Phase 3 include edotecarin (Pfizer) and enzastaurin (Eli Lilly and Company).
SI-053 differentiates through its intracranial delivery mechanism, which aims to achieve high local drug concentration while potentially reducing systemic exposure. However, this approach remains unproven clinically. The Phase 1 program must demonstrate acceptable safety and tolerability before efficacy can be assessed. Competitive advantage will depend on Phase 2 efficacy data, manufacturing feasibility, and clinical outcomes relative to systemic temozolomide combinations currently in late-stage development.
| Therapy | Company | Mechanism | Status |
|---|---|---|---|
| Stereotactic Radiation Therapy | GT Biopharma | other | approved |
| IRON OXIDE (E172) | Disc Medicine | small_molecule | approved |
| Surgical tumor resection, GammaTile radiation therapy implantation, Stupp protocol (EBRT and Temozolamide) | GT Biopharma | other | approved |
| Temozolomide | Adaptive Biotechnologies Corp | small_molecule | phase_3 |
| Cediranib | AstraZeneca | small_molecule | phase_3 |
| TEMOZOLOMIDE , KEYTRUDA 25 mg/mL concentrate for solution for infusion, saline solution for infusion | Novo Nordisk A/S | small_molecule | phase_3 |
| LOMUSTINE, 4-L-[131I]iodo-phenylalanine, LOMUSTINE | Lacuna Pharma Pty Ltd | small_molecule | phase_3 |
| Temodal 100 mg hard capsules, Temodal 250 mg hard capsules, Placebo, 2-Hydroxyoleic acid sodium salt, Temodal 140 mg hard capsules, Temodal 5 mg hard capsules, Temodal 20 mg hard capsules, Temodal 180 mg hard capsules | Lacuna Pharma Pty Ltd | small_molecule | phase_3 |
| ADI-PEG-20, Troriluzole, AZD1390 | Adaptive Biotechnologies Corp | small_molecule | phase_3 |
| enzastaurin | Eli Lilly and Company | small_molecule | phase_3 |
| Edotecarin | Pfizer | small_molecule | phase_3 |
| LOMUSTINE | Ningbo Cancer Hospital | small_molecule | phase_3 |
| CARMUSTINE | — | Glutathione reductase inhibitor | Approved |
| BEVACIZUMAB | — | Vascular endothelial growth factor A inhibitor | Approved |
| TRABEDERSEN | — | Transforming growth factor beta-2 mRNA antisense inhibitor | Phase 3 |
| TOFACITINIB | — | Janus Kinase (JAK) inhibitor | Phase 3 |
| RINDOPEPIMUT | — | Epidermal growth factor receptor erbB1 vaccine antigen | Phase 3 |
| OMBIPEPIMUT-S | — | Wilms tumor protein vaccine antigen | Phase 3 |
| NIVOLUMAB | — | Programmed cell death protein 1 inhibitor | Phase 3 |
| NIMOTUZUMAB | — | Epidermal growth factor receptor erbB1 inhibitor | Phase 3 |
Additional associated therapies sourced from Open Targets Platform (CC0), linked to NovaPharmaNews drug profiles where matched.
FDA Status: Not yet disclosed. SI-053 is in Phase 1 development and has not filed an Investigational New Drug (IND) application status disclosure or received FDA guidance letters that are publicly available in the facts provided.
EMA Status: Not yet disclosed.
PMDA (Japan) Status: Not yet disclosed.
NMPA (China) Status: Not yet disclosed.
Note on Related Compounds: Temozolomide (the active pharmaceutical ingredient backbone) is approved globally for GBM treatment. Desmopressin acetate (MINIRIN), listed in the drug data, is approved in the US under multiple ANDA and NDA applications but is unrelated to SI-053 and appears to be a data entry artifact.
The Phase 1 trial is registered under NCT identifier 2024-515128-35-00, indicating active enrollment. Regulatory pathway and breakthrough designation status are not yet disclosed.
SI-053 is an investigational temozolomide-based therapy being developed by Lacuna Pharma Pty Ltd for intracranial administration in newly diagnosed glioblastoma (GBM), an aggressive primary brain tumor in adults.
SI-053 is administered intracranially (directly into the brain) as a single dose, in addition to standard of care treatment (external beam radiation therapy and systemic temozolomide).
The specific mechanism of action has not yet been disclosed. SI-053 is based on temozolomide, which typically works by alkylating DNA to inhibit tumor cell growth.
SI-053 is currently in Phase 1 development, conducting an open-label dose escalation study to determine the maximum tolerated dose (MTD), identify dose-limiting toxicities (DLTs), and characterize pharmacokinetics.
No, SI-053 is not approved by the FDA or any other regulatory agency. It is an investigational drug in early-stage clinical development.
Lacuna Pharma Pty Ltd, an Australian pharmaceutical company, is the sponsor of SI-053.
The Phase 1 trial is registered as NCT 2024-515128-35-00.
The primary endpoints are estimation of the maximum tolerated dose (MTD) and identification of dose-limiting toxicities (DLTs) following a single intracranial dose of SI-053.
The Phase 1 study enrolls adult patients with newly diagnosed glioblastoma who are receiving standard of care treatment.
Intracranial delivery aims to achieve high local drug concentrations at the tumor site while potentially reducing systemic toxicity compared to intravenous temozolomide administration.
Competitors include systemic temozolomide combinations with checkpoint inhibitors (e.g., pembrolizumab), anti-angiogenic agents (e.g., cediranib), alternative chemotherapy agents (e.g., lomustine, edotecarin), and established surgical and radiation-based approaches.
Despite aggressive multimodal therapy, median overall survival in newly diagnosed GBM is approximately 15 months, and recurrent disease is nearly universal. Novel treatment approaches are urgently needed.
The expected timeline for Phase 1 results has not been disclosed in the available facts.
Breakthrough designation or expedited review status has not been disclosed in the available facts.
The standard of care (Stupp protocol) consists of maximal surgical resection followed by external beam radiation therapy concurrent with and followed by systemic temozolomide chemotherapy.
No partnerships or licensing agreements have been disclosed in the available facts; SI-053 is being developed solely by Lacuna Pharma Pty Ltd.
Approximately 10,000–12,000 new GBM diagnoses occur annually in the United States alone. Commercial success depends on Phase 2 efficacy data, tolerability, manufacturing feasibility, and competitive positioning relative to systemic temozolomide combinations in late-stage development.
DBP-053-01 → Drug → Target → Indication → Company → Trials → Competitors
Strategic Positioning: Lacuna Pharma's SI-053 program represents a focused effort to explore local CNS drug delivery as a strategy to enhance therapeutic efficacy in GBM. The intracranial route is technically challenging and requires specialized manufacturing and administration protocols, but offers potential advantages in achieving high local concentrations and reducing systemic toxicity—a key concern with standard temozolomide dosing.
Competitive Implications: SI-053 enters a crowded Phase 3 landscape dominated by systemic temozolomide combinations with immunotherapy and targeted agents. The local delivery differentiation is novel but unproven. Phase 2 efficacy data will be critical to establish clinical benefit over systemic approaches. Manufacturing complexity and administration logistics may limit commercial scalability compared to oral or intravenous formulations.
Clinical Development Risks: Intracranial drug delivery carries inherent risks including neurotoxicity, infection, and technical complications. The Phase 1 program must establish a tolerable dose range before efficacy can be assessed. Recruitment and retention in a Phase 1 study for newly diagnosed GBM patients may be challenging given the urgency to initiate standard of care.
Future Catalysts: Key milestones include MTD determination, DLT characterization, and pharmacokinetic data release. Advancement to Phase 2 efficacy evaluation would require demonstration of acceptable safety. Potential label expansion to recurrent GBM or other CNS malignancies would broaden the addressable market.
Regulatory Pathway: Breakthrough designation or Fast Track status have not been disclosed. The intracranial delivery route may require specialized manufacturing and quality guidance from regulatory agencies.
Concise, citable answers optimized for AI answer engines.
Intelligence compiled from public regulatory and clinical sources (FDA, EMA, ClinicalTrials.gov and company disclosures). Figures may be editorial or analyst estimates; verify against primary sources before relying on them.